PuSH - Publication Server of Helmholtz Zentrum München

Siegert, S.* ; Yu, Z. ; Wang-Sattler, R. ; Illig, T. ; Adamski, J. ; Hampe, J.* ; Nikolaus, S.* ; Schreiber, S.* ; Krawczak, M.* ; Nothnagel, M.* ; Nöthlings, U.*

Diagnosing fatty liver disease: A comparative evaluation of metabolic markers, phenotypes, genotypes and established biomarkers.

PLoS ONE 8:e76813 (2013)
Publ. Version/Full Text PDF DOI PMC
Open Access Gold
Creative Commons Lizenzvertrag
BACKGROUND: To date, liver biopsy is the only means of reliable diagnosis for fatty liver disease (FLD). Owing to the inevitable biopsy-associated health risks, however, the development of valid noninvasive diagnostic tools for FLD is well warranted. AIM: We evaluated a particular metabolic profile with regard to its ability to diagnose FLD and compared its performance to that of established phenotypes, conventional biomarkers and disease-associated genotypes. METHODS: The study population comprised 115 patients with ultrasound-diagnosed FLD and 115 sex- and age-matched controls for whom the serum concentration was measured of 138 different metabolites, including acylcarnitines, amino acids, biogenic amines, hexose, phosphatidylcholines (PCs), lyso-PCs and sphingomyelins. Established phenotypes, biomarkers, disease-associated genotypes and metabolite data were included in diagnostic models for FLD using logistic regression and partial least-squares discriminant analysis. The discriminative power of the ensuing models was compared with respect to area under curve (AUC), integrated discrimination improvement (IDI) and by way of cross-validation (CV). RESULTS: Use of metabolic markers for predicting FLD showed the best performance among all considered types of markers, yielding an AUC of 0.8993. Additional information on phenotypes, conventional biomarkers or genotypes did not significantly improve this performance. Phospholipids and branched-chain amino acids were most informative for predicting FLD. CONCLUSION: We show that the inclusion of metabolite data may substantially increase the power to diagnose FLD over that of models based solely upon phenotypes and conventional biomarkers.  
Impact Factor
Scopus SNIP
Web of Science
Times Cited
Scopus
Cited By
Altmetric
3.730
1.063
8
8
Tags
Annotations
Special Publikation
Hide on homepage

Edit extra information
Edit own tags
Private
Edit own annotation
Private
Hide on publication lists
on hompage
Mark as special
publikation
Publication type Article: Journal article
Document type Scientific Article
Keywords Whole-genome Association ; Insulin-resistance ; Nonalcoholic Steatohepatitis ; General-population ; Lipid-metabolism ; Index ; Epidemiology ; Genetics ; Risk ; Prediction
Language english
Publication Year 2013
HGF-reported in Year 2013
ISSN (print) / ISBN 1932-6203
Journal PLoS ONE
Quellenangaben Volume: 8, Issue: 10, Pages: , Article Number: e76813 Supplement: ,
Publisher Public Library of Science (PLoS)
Publishing Place Lawrence, Kan.
Reviewing status Peer reviewed
Institute(s) Research Unit Molecular Epidemiology (AME)
Molekulare Endokrinologie und Metabolismus (MEM)
POF-Topic(s) 30501 - Systemic Analysis of Genetic and Environmental Factors that Impact Health
30201 - Metabolic Health
Research field(s) Genetics and Epidemiology
PSP Element(s) G-504200-003
G-505600-001
PubMed ID 24130792
Scopus ID 84885124263
Erfassungsdatum 2013-10-21